
Obrixtamig Plus Topotecan Shows Tolerability, Efficacy in Advanced ES-SCLC
The addition of topotecan (Hycamtin) to obrixtamig (BI 764532) exhibited tolerability and promising preliminary efficacy in patients with advanced extensive-stage small cell lung cancer (ES-SCLC), according to findings from the phase 1 DAREON®-9 trial ( …